Cargando…
Extensive deep vein thrombosis treatment using fondaparinux and edoxaban: a case report
BACKGROUND: Factor Xa inhibitor is a key drug in the coagulation cascade. Parenteral anticoagulation using low molecular weight heparin or fondaparinux is the recommended form of treatment for most patients presenting with venous thrombosis. Following the acute phase, edoxaban is recommended. We pre...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4962499/ https://www.ncbi.nlm.nih.gov/pubmed/27468257 http://dx.doi.org/10.1186/s12959-016-0089-x |
_version_ | 1782444849409032192 |
---|---|
author | Shimizu, Kazuhiro Sasaki, Takeshi Tomaru, Takanobu Noike, Hirofumi |
author_facet | Shimizu, Kazuhiro Sasaki, Takeshi Tomaru, Takanobu Noike, Hirofumi |
author_sort | Shimizu, Kazuhiro |
collection | PubMed |
description | BACKGROUND: Factor Xa inhibitor is a key drug in the coagulation cascade. Parenteral anticoagulation using low molecular weight heparin or fondaparinux is the recommended form of treatment for most patients presenting with venous thrombosis. Following the acute phase, edoxaban is recommended. We present a case of extensive deep vein thrombosis treated using fondaparinux and edoxaban. CASE PRESENTATION: A 63-year-old man with redness, pain, and swelling of the left leg lasting for more than 1 month was referred to our hospital. Ultrasonography revealed a thrombus in the left femoral vein. Computed tomographic angiography revealed clots in the distal right pulmonary artery. Thus, the anticoagulant treatment was initiated with subcutaneous injections of fondaparinux (7.5 mg) for 5 consecutive days, followed by once daily oral administration of edoxaban (60 mg). After 3 months of treatment, a regression of thrombotic clots was shown. Three months later, the remaining clots disappeared, leaving only mural thrombi; no bleeding complications were observed during the treatment period. CONCLUSION: The anticoagulant treatment with subcutaneous fondaparinux and subsequently with oral edoxaban was effective for treating extensive deep vein thrombosis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12959-016-0089-x) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4962499 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-49624992016-07-28 Extensive deep vein thrombosis treatment using fondaparinux and edoxaban: a case report Shimizu, Kazuhiro Sasaki, Takeshi Tomaru, Takanobu Noike, Hirofumi Thromb J Case Report BACKGROUND: Factor Xa inhibitor is a key drug in the coagulation cascade. Parenteral anticoagulation using low molecular weight heparin or fondaparinux is the recommended form of treatment for most patients presenting with venous thrombosis. Following the acute phase, edoxaban is recommended. We present a case of extensive deep vein thrombosis treated using fondaparinux and edoxaban. CASE PRESENTATION: A 63-year-old man with redness, pain, and swelling of the left leg lasting for more than 1 month was referred to our hospital. Ultrasonography revealed a thrombus in the left femoral vein. Computed tomographic angiography revealed clots in the distal right pulmonary artery. Thus, the anticoagulant treatment was initiated with subcutaneous injections of fondaparinux (7.5 mg) for 5 consecutive days, followed by once daily oral administration of edoxaban (60 mg). After 3 months of treatment, a regression of thrombotic clots was shown. Three months later, the remaining clots disappeared, leaving only mural thrombi; no bleeding complications were observed during the treatment period. CONCLUSION: The anticoagulant treatment with subcutaneous fondaparinux and subsequently with oral edoxaban was effective for treating extensive deep vein thrombosis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12959-016-0089-x) contains supplementary material, which is available to authorized users. BioMed Central 2016-07-27 /pmc/articles/PMC4962499/ /pubmed/27468257 http://dx.doi.org/10.1186/s12959-016-0089-x Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Case Report Shimizu, Kazuhiro Sasaki, Takeshi Tomaru, Takanobu Noike, Hirofumi Extensive deep vein thrombosis treatment using fondaparinux and edoxaban: a case report |
title | Extensive deep vein thrombosis treatment using fondaparinux and edoxaban: a case report |
title_full | Extensive deep vein thrombosis treatment using fondaparinux and edoxaban: a case report |
title_fullStr | Extensive deep vein thrombosis treatment using fondaparinux and edoxaban: a case report |
title_full_unstemmed | Extensive deep vein thrombosis treatment using fondaparinux and edoxaban: a case report |
title_short | Extensive deep vein thrombosis treatment using fondaparinux and edoxaban: a case report |
title_sort | extensive deep vein thrombosis treatment using fondaparinux and edoxaban: a case report |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4962499/ https://www.ncbi.nlm.nih.gov/pubmed/27468257 http://dx.doi.org/10.1186/s12959-016-0089-x |
work_keys_str_mv | AT shimizukazuhiro extensivedeepveinthrombosistreatmentusingfondaparinuxandedoxabanacasereport AT sasakitakeshi extensivedeepveinthrombosistreatmentusingfondaparinuxandedoxabanacasereport AT tomarutakanobu extensivedeepveinthrombosistreatmentusingfondaparinuxandedoxabanacasereport AT noikehirofumi extensivedeepveinthrombosistreatmentusingfondaparinuxandedoxabanacasereport |